Obesity Clinical Trial
— HEPPE-PSMIOfficial title:
Development and Evaluation of a Health Education Programme Through Physical Exercise for the Development of Autonomous Physical Activity Habits in People With Severe Mental Disorders
Verified date | September 2023 |
Source | Fundación para la Investigación del Hospital Clínico de Valencia |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this clinical trial is to [learn about, test, compare etc.] in individuals with severe mental disorders and obesity comorbid. The main question[s] it aims to answer are: - Are inflammatory activity, oxidative and vascular damage and metabolic mechanisms, as well as neurocognitive and functional performance, related to different physical exercise interventions? - Do inflammatory, oxidative stress and cardiometabolic biomarkers predict neurocognitive improvement after physical activity training? Participants will guided-exercise of moderate intensity and frecuency, and incentive of autonomous physical activity proposals by the specialist; guided physical activity group (GPAG), or (b) 12 weeks of an exercise program standard physical activity without guided and incentives; standard physical activity group (SPAG). If there is a comparison group: Researchers will compare GPAG and SPAG to see if inflammatory, oxidative stress, and cardio-metabolic biomarkers improve neurocognitive performance after physical activity training
Status | Completed |
Enrollment | 29 |
Est. completion date | June 30, 2016 |
Est. primary completion date | June 30, 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - MDD, BD and SZ were diagnosed according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders - DSM-5 (APA, 2014). - Participants with MDD and BD should meet the remission criteria (Tohen et al., 2009) of an acute affective episode, defined as Young Mania Rating Scale (YMRS) score = 6 and Hamilton Rating Scale for Depression (HRSD) score = 8, and individuals with SZ had to be clinically stable, defined as Positive and Negative Syndrome Scale (PANSS) score = 36. - The comorbid OB diagnosis was based on World Health Organization (WHO) criteria. - Ability to understand study procedures and willingness to give written consent was required for participation. For recruitment as HC - Absence of physical illness - Absence of pharmacological treatments - Absence of family history of psychiatric disorders in first-degree relatives were required. - Ability to understand study procedures and willingness to give written consent was required for participation. Exclusion Criteria: - current hospitalization - documented cognitive impairment not secondary to psychiatric disorder (intellectual disability or major neurocognitive disorder, i.e. dementia) - disability or inability that prevented understanding of the protocol - current substance use disorders (except for nicotine) - pregnancy - intake of steroids - corticosteroids, antioxidants, antibiotics, and immunologic therapies - fever over 38°C - history of vaccination within 4 weeks of the evaluation - medical contraindications for exercise - body mass index = 40 - diastolic/systolic blood pressure = 140/90 - resting heart rate = 100. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Fundación para la Investigación del Hospital Clínico de Valencia |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Verbal learning and memory | Complutense Verbal Learning Test total immediate recall, short-term free recall and long-term free recall The higher scores mean a better outcome. | 4 months | |
Primary | Cognitive flexibility | Wisconsin Card Sorting Test The higher scores mean a better outcome. | 4 months | |
Primary | Verbal fluency | Animal naming test for phonemic and semantic fluency. The higher scores mean a better outcome. | 4 months | |
Primary | Working memory | Trail Making Test The higher scores mean a better outcome. | 4 months | |
Primary | Short-term memory | Complutense Verbal Learning Test total immediate recall, short-term free recall and long-term free recall The higher scores mean a better outcome. | 4 months | |
Primary | Visual memory | Rey-Osterrieth Complex Figure Test figure two minutes after the copy and 20 minutes after the copy.
The higher scores mean a better outcome. |
4 months | |
Primary | Processing speed | Stroop Color and Word test color/word subtest The higher scores mean a better outcome. | 4 months | |
Primary | Functional Assessment Short Test | Functional performance. The higher scores mean a better outcome. | 4 months | |
Primary | Short Form-36 Health Survey questionnaire | Quality of life. The higher scores mean a better outcome. | 4 months | |
Primary | World Health Organization Quality of Life brief scale | Quality of life. The higher scores mean a better outcome. | 4 months | |
Primary | Inflammatory markers | Serum cytokine concentrations were determined using Luminex® X-MAP technology (Luminex Corp., Austin, TX, USA) based on flow cytometry. Sample processing and data analysis were performed according to the manufacturer's instructions. (Behring Nephelometer II, Dade Behring, Inc., Newark, DE, USA).. | 4 months | |
Primary | Oxidative stress markers | Oxidative stress in leukocytes was evaluated using fluorimetry techniques with a fluoroscan (Synergy MX). In total, 100 000 cells were plated in each well of 96-well plates and incubated for 30 min at 37 °C with the corresponding fluorochromes, as follows: dichlorofluorescein diacetate to measure reactive oxygen species (ROS) production (485 nm excitation, 535 nm emission), MitoSOX to measure mitochondrial ROS (mROS) (510 nm excitation, 580 nm emission), tetramethylrodamin methyl ester to assess mitochondrial membrane potential (552 nm excitation, 574 nm emission), nonylacridin orange mitochondrial mass (495 nm excitation, 519 nm emission), and 5-chloromethylfluorescein diacetate to measure intracellular glutathione (492 nm excitation, 517 nm emission). The monocyte cell line U-937 was used as an internal control to avoid potential fluctuations in fluorescence over time. | 4 months | |
Primary | Adhesion molecules markers | Serum lipid peroxidation levels were measured using a commercial thiobarbituric acid reactive substances (TBARS) kit according to the manufacturer's instructions (Olympus, Hamburg, Germany). A Luminex 200 flow analyzer system (Austin, TX, USA) was employed to analyze adhesion molecules in serum. To measure immunological markers, citrated blood samples were incubated with dextran (3%) for 45 min to isolate human polymorphonuclear leukocytes (PMNs). The supernatant was layered over Ficoll-Hypaque (GE Healthcare, Barcelona, Spain) and centrifuged for 25 min at room temperature at 650g. Lysis buffer was added to the remaining erythrocytes in the pellet, which were incubated at room temperature for 5 min and then spun at 240g for 5 min. PMNs were rinsed twice and resuspended at 37 ? in Hanks' balanced salt solution (Sigma Aldrich, MO). Scepter 2.0 cell counters (Millipore, MA, USA) was employed to count cells | 4 months | |
Primary | Metabolic markers | Under aseptic conditions, fasting venous blood samples were collected between 8 and 9 am to measure. | 4 months | |
Primary | Maximum heart rate | Measured with a watch-shaped device that was worn on the wrist and captured the beats per minute. | 4 months | |
Primary | Systolic pressure/diastolic pressure | Measured on the right arm using an automatic sphygmomanometer with participants in the sitting position after resting for 5 minutes. | 4 months | |
Primary | Waist circumference | Measured in the standing position at the end of normal expiration and at the midway between the inferior costal margin and the superior border of the iliac crest. | 4 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |